Aurinia Pharmaceuticals Inc
AUPH7.490USD
+0.010+0.13%
Close 07/02, 16:00（ET）Quotes delayed by 15 min
1.03BMarket Cap
25.89P/E TTM
More Details of Aurinia Pharmaceuticals Inc Company
Aurinia Pharmaceuticals Inc. is a fully integrated biopharmaceutical company. The Company is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. It has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. The Company is primarily engaged in the development of its pipeline asset AUR200, a differentiated, potential next generation therapy for autoimmune diseases that targets both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand). The Company contracted with Otsuka Pharmaceutical Co., Ltd. (Otsuka) as a collaboration partner for the development and commercialization of LUPKYNIS in the Otsuka Territories. It sells LUPKYNIS (voclosporin) primarily to specialty pharmacies and a specialty distributor and directly to its ex-U.S. partner, Otsuka.
Company Info
Ticker SymbolAUPH
Company nameAurinia Pharmaceuticals Inc
IPO dateJul 16, 2001
Founded at2009
CEOMr. Peter S. Greenleaf
Number of employees130
Security typeOrdinary Share
Fiscal year-endJul 16
Address#140, 14315 - 118 Avenue
CityEDMONTON
Stock exchangeNASDAQ Global Market Consolidated
CountryCanada
Postal codeT5L 4S6
Phone12507442487
Websitehttps://www.auriniapharma.com
Ticker SymbolAUPH
IPO dateJul 16, 2001
Founded at2009
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Peter S. Greenleaf
Mr. Peter S. Greenleaf
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
667.87K
+16.06%
Mr. Stephen P. Robertson
Mr. Stephen P. Robertson
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
176.21K
+23.75%
Ms. Jill Diane Leversage
Ms. Jill Diane Leversage
Independent Director
Independent Director
12.92K
-17.94%
Dr. Greg Keenan
Dr. Greg Keenan
Chief Medical Officer
Chief Medical Officer
10.51K
-93.15%
Mr. Joseph Miller
Mr. Joseph Miller
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Andrea Christopher
Ms. Andrea Christopher
Executive Director, Corporate Communications and Investor Relations
Executive Director, Corporate Communications and Investor Relations
--
--
Dr. Karen Lesley Smith, M.D., Ph.D.
Dr. Karen Lesley Smith, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Kevin Tang
Mr. Kevin Tang
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. David R.W Jayne, M.D.
Dr. David R.W Jayne, M.D.
Independent Director
Independent Director
--
--
Mr. Craig Johnson
Mr. Craig Johnson
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Peter S. Greenleaf
Mr. Peter S. Greenleaf
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
667.87K
+16.06%
Mr. Stephen P. Robertson
Mr. Stephen P. Robertson
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
176.21K
+23.75%
Ms. Jill Diane Leversage
Ms. Jill Diane Leversage
Independent Director
Independent Director
12.92K
-17.94%
Dr. Greg Keenan
Dr. Greg Keenan
Chief Medical Officer
Chief Medical Officer
10.51K
-93.15%
Mr. Joseph Miller
Mr. Joseph Miller
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Andrea Christopher
Ms. Andrea Christopher
Executive Director, Corporate Communications and Investor Relations
Executive Director, Corporate Communications and Investor Relations
--
--
Revenue Breakdown
Currency: USDUpdated: 7 hours ago
Currency: USDUpdated: 7 hours ago
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
No Data
By RegionUSD
Name
Revenue
Proportion
US
210.09M
89.35%
Japan
25.04M
10.65%
Other
0.00
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, Jul 2
Updated: Wed, Jul 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Tang Capital Management, LLC
7.42%
ILJIN SNT Co., Ltd.
6.57%
BlackRock Institutional Trust Company, N.A.
5.53%
Armistice Capital LLC
3.70%
New Enterprise Associates (NEA)
2.94%
Other
73.84%
Shareholders
Shareholders
Proportion
Tang Capital Management, LLC
7.42%
ILJIN SNT Co., Ltd.
6.57%
BlackRock Institutional Trust Company, N.A.
5.53%
Armistice Capital LLC
3.70%
New Enterprise Associates (NEA)
2.94%
Other
73.84%
Shareholder Types
Shareholders
Proportion
Hedge Fund
14.35%
Investment Advisor
12.78%
Investment Advisor/Hedge Fund
12.71%
Corporation
6.57%
Venture Capital
3.02%
Research Firm
2.96%
Individual Investor
2.80%
Pension Fund
0.52%
Bank and Trust
0.35%
Other
43.95%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
436
77.25M
57.17%
-345.00
2025Q1
457
75.49M
55.51%
-3.25M
2024Q4
454
71.04M
51.53%
-9.95M
2024Q3
449
70.86M
49.85%
-8.98M
2024Q2
452
69.33M
48.80%
-9.83M
2024Q1
446
69.12M
48.16%
-8.26M
2023Q4
460
67.04M
46.69%
-7.24M
2023Q3
469
63.17M
44.06%
-14.31M
2023Q2
493
65.34M
45.61%
-23.55M
2023Q1
499
65.33M
45.73%
-27.23M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Tang Capital Management, LLC
10.03M
7.42%
+1.60M
+18.98%
Mar 31, 2025
ILJIN SNT Co., Ltd.
8.88M
6.57%
+2.48M
+38.78%
Apr 12, 2025
BlackRock Institutional Trust Company, N.A.
7.47M
5.53%
-150.03K
-1.97%
Mar 31, 2025
Armistice Capital LLC
5.00M
3.7%
-1.40M
-21.88%
Mar 31, 2025
New Enterprise Associates (NEA)
3.97M
2.94%
--
--
Mar 31, 2025
State Street Global Advisors (US)
2.85M
2.11%
-66.87K
-2.29%
Mar 31, 2025
The Vanguard Group, Inc.
1.94M
1.44%
+241.86K
+14.20%
Mar 31, 2025
Morgan Stanley & Co. LLC
1.74M
1.29%
+754.77K
+76.56%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.73M
1.28%
-30.09K
-1.71%
Mar 31, 2025
Arrowstreet Capital, Limited Partnership
1.64M
1.21%
+564.52K
+52.47%
Mar 31, 2025
View more
Related ETFs
Updated: 19 hours ago
Updated: 19 hours ago
Name
Proportion
Virtus LifeSci Biotech Products ETF
1.48%
ALPS Medical Breakthroughs ETF
0.93%
Janus Henderson Small Cap Growth Alpha ETF
0.7%
SPDR S&P International Small Cap ETF
0.14%
Invesco Nasdaq Biotechnology ETF
0.12%
ProShares Ultra Nasdaq Biotechnology
0.12%
Vanguard US Momentum Factor ETF
0.1%
iShares Biotechnology ETF
0.1%
Vanguard US Multifactor ETF
0.1%
Avantis US Small Cap Equity ETF
0.09%
View more
Virtus LifeSci Biotech Products ETF
Proportion1.48%
ALPS Medical Breakthroughs ETF
Proportion0.93%
Janus Henderson Small Cap Growth Alpha ETF
Proportion0.7%
SPDR S&P International Small Cap ETF
Proportion0.14%
Invesco Nasdaq Biotechnology ETF
Proportion0.12%
ProShares Ultra Nasdaq Biotechnology
Proportion0.12%
Vanguard US Momentum Factor ETF
Proportion0.1%
iShares Biotechnology ETF
Proportion0.1%
Vanguard US Multifactor ETF
Proportion0.1%
Avantis US Small Cap Equity ETF
Proportion0.09%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
